Papworth Karin, Bergh Anders, Grankvist Kjell, Ljungberg Börje, Rasmuson Torgny
Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Tumour Biol. 2009;30(2):86-92. doi: 10.1159/000216844. Epub 2009 May 4.
To investigate the prognostic impact of erythropoietin (EPO) and EPO-receptor (EPO-R) expression in tumour as well as serum EPO in patients with renal cell carcinoma (RCC).
Using immunohistochemistry, EPO and EPO-R were assessed in tissue microarrays from 195 RCCs. RCC type, TNM stage, nuclear grade, survival, EPO and haemoglobin (Hb) levels in blood were registered.
Strong expression of EPO and EPO-R in tumour tissue was found in 83 and 56%, respectively. EPO and EPO-R expression differed between RCC types. Serum EPO and blood Hb did not correlate to the expression of EPO or EPO-R. A positive correlation was found between the expression of EPO and EPO-R (p = 0.028). Survival was not related to tumour EPO, whereas strong EPO-R expression indicated a non-significantly worse prognosis. Serum EPO correlated positively to TNM stage and nuclear grade and negatively to survival. A multivariate analysis showed that TNM stage and nuclear grade were independent prognostic factors. Tumour EPO and EPO-R expression as well as serum EPO added no independent prognostic information.
No correlation between EPO or EPO-R in tumour tissue and serum EPO or blood Hb was found. Neither EPO, EPO-R in tumour tissue nor serum EPO are independent prognostic factors.
研究促红细胞生成素（EPO）和EPO受体（EPO-R）在肿瘤中的表达以及血清EPO对肾细胞癌（RCC）患者预后的影响。
采用免疫组织化学方法，对195例RCC组织芯片中的EPO和EPO-R进行评估。记录RCC类型、TNM分期、核分级、生存率、血液中的EPO和血红蛋白（Hb）水平。
肿瘤组织中EPO和EPO-R的强表达分别见于83%和56%的病例。EPO和EPO-R的表达在不同RCC类型之间存在差异。血清EPO和血液Hb与EPO或EPO-R的表达无关。EPO和EPO-R的表达之间存在正相关（p = 0.028）。生存率与肿瘤EPO无关，而EPO-R的强表达提示预后稍差但无统计学意义。血清EPO与TNM分期和核分级呈正相关，与生存率呈负相关。多因素分析显示TNM分期和核分级是独立的预后因素。肿瘤EPO和EPO-R的表达以及血清EPO均未增加独立的预后信息。
未发现肿瘤组织中的EPO或EPO-R与血清EPO或血液Hb之间存在相关性。肿瘤组织中的EPO、EPO-R以及血清EPO均不是独立的预后因素。
